RBC Capital analyst Ryan Halsted initiated coverage of Iqvia (IQV) with an Outperform rating and $221 price target The firm sees numerous data points suggesting an increase in clinical trial activity into 2026. Iqvia is positioned to benefit from an “inflection” in the contract research organization market more than others based on its “unique” data analytics capabilities built with over 64 petabytes of data, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia to acquire certain discovery services assets from Charles River
- Iqvia price target lowered to $215 from $266 at Mizuho
- Iqvia price target lowered to $245 from $290 at Truist
- Iqvia price target lowered to $174 from $245 at TD Cowen
- IQVIA: Solid 2026 Outlook but AI Disruption Risks Justify Hold Rating and Lowered Valuation